File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Web of Science: 0
- Appears in Collections:
Conference Paper: Serum HBcrAg Profiles in Chronic Hepatitis B Patients Treated With First-Line Oral Antiviral Therapy
Title | Serum HBcrAg Profiles in Chronic Hepatitis B Patients Treated With First-Line Oral Antiviral Therapy |
---|---|
Authors | |
Issue Date | 2019 |
Publisher | John Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/ |
Citation | The 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD): The Liver Meeting 2019, Boston, MA, USA, 8-12 November 2019. In Hepatology, 2019, v. 70 n. Suppl. 1, p. 292A, abstract no. 461 How to Cite? |
Abstract | Background: Serum hepatitis B core-related antigen
(HBcrAg) is a potential surrogate marker for intra-hepatic covalently-closed circular DNA in chronic hepatitis B (CHB) . We aimed to study the profiles of serum HBcrAg in CHB patients treated with first-line oral nucleos(t)ide analogues (NA): entecavir (ETV), tenofovir disoproxil fumarate (TDF)
or tenofovir alafenamide (TAF) . Methods: Serum HBcrAg was measured in 264 NA-treated CHB patients (ETV: TDF: TAF = 197: 30: 37) using the Lumipulse G HBcrAg assay in a Lumipulse G1200 analyzer (Fujirebio Inc, Toyko, Japan) with
a lower detection limit of 100 units per milliliter (U/ml) . The values of HBcrAg were log transformed and were expressed in log U/mL . Serum HBcrAg levels were measured at baseline,
48-week and 96-week of NA therapy . Results: Among the 264 patients, 130 (49 .2%) were hepatitis B e antigen (HBeAg) positive . In this interim report, HBcrAg level measurements
were completed for all 3 groups of patients at baseline and week 48 and for TDF and TAF treated patients at week 96 . All 3 first-line NAs led to significant decline of serum HBcrAg at
48-week compared to baseline (ETV: 1.97 vs. 3.02, TDF: 2.88 vs. 4.49, and TAF: 3.00 vs. 4.36, respectively; all p <0.001).
For TDF and TAF, further decline of HBcrAg was observed at 96-week compared to 48-week (TDF: 2.09 vs. 2.88, and TAF 1.89 vs. 3.00, respectively; both p<0.01) [figure]. However, when only HBeAg-negative patients were analyzed, the drop in HBcrAg at 96-week compared to 48-week was not
significant for both TDF and TAF treated patients (0.62 vs. 1.08 and 0.56 vs. 0.80, respectively; both p>0.05). There were no significant differences for the magnitude of HBcrAg decline at 48-week between the 3 different types of NAs (ETV:
1.088; TDF: 1.437; TAF: 1.318; p>0.05 for all 3 comparisons). Similarly, TDF and TAF produced no significant differences in the magnitude of HBcrAg decline at 96-week (2 .20 vs . 1 .74, p>0.05). Conclusion: The 3 first-line NAs showed similar
potencies in suppression of viral activity upon 1 year duration of therapy. The lack of significant drop of HBcrAg in HBeAgnegative patients reflects the limited utility of this marker in HBeAg-negative phase. [https://doi.org/10.1002/hep.30941 ] |
Description | Poster Abstract - no. 461 |
Persistent Identifier | http://hdl.handle.net/10722/280920 |
ISSN | 2023 Impact Factor: 12.9 2023 SCImago Journal Rankings: 5.011 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mak, LY | - |
dc.contributor.author | Wong, DKH | - |
dc.contributor.author | Seto, WKW | - |
dc.contributor.author | Fung, JYY | - |
dc.contributor.author | Lai, CL | - |
dc.contributor.author | Yuen, RMF | - |
dc.date.accessioned | 2020-02-25T07:42:46Z | - |
dc.date.available | 2020-02-25T07:42:46Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | The 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD): The Liver Meeting 2019, Boston, MA, USA, 8-12 November 2019. In Hepatology, 2019, v. 70 n. Suppl. 1, p. 292A, abstract no. 461 | - |
dc.identifier.issn | 0270-9139 | - |
dc.identifier.uri | http://hdl.handle.net/10722/280920 | - |
dc.description | Poster Abstract - no. 461 | - |
dc.description.abstract | Background: Serum hepatitis B core-related antigen (HBcrAg) is a potential surrogate marker for intra-hepatic covalently-closed circular DNA in chronic hepatitis B (CHB) . We aimed to study the profiles of serum HBcrAg in CHB patients treated with first-line oral nucleos(t)ide analogues (NA): entecavir (ETV), tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF) . Methods: Serum HBcrAg was measured in 264 NA-treated CHB patients (ETV: TDF: TAF = 197: 30: 37) using the Lumipulse G HBcrAg assay in a Lumipulse G1200 analyzer (Fujirebio Inc, Toyko, Japan) with a lower detection limit of 100 units per milliliter (U/ml) . The values of HBcrAg were log transformed and were expressed in log U/mL . Serum HBcrAg levels were measured at baseline, 48-week and 96-week of NA therapy . Results: Among the 264 patients, 130 (49 .2%) were hepatitis B e antigen (HBeAg) positive . In this interim report, HBcrAg level measurements were completed for all 3 groups of patients at baseline and week 48 and for TDF and TAF treated patients at week 96 . All 3 first-line NAs led to significant decline of serum HBcrAg at 48-week compared to baseline (ETV: 1.97 vs. 3.02, TDF: 2.88 vs. 4.49, and TAF: 3.00 vs. 4.36, respectively; all p <0.001). For TDF and TAF, further decline of HBcrAg was observed at 96-week compared to 48-week (TDF: 2.09 vs. 2.88, and TAF 1.89 vs. 3.00, respectively; both p<0.01) [figure]. However, when only HBeAg-negative patients were analyzed, the drop in HBcrAg at 96-week compared to 48-week was not significant for both TDF and TAF treated patients (0.62 vs. 1.08 and 0.56 vs. 0.80, respectively; both p>0.05). There were no significant differences for the magnitude of HBcrAg decline at 48-week between the 3 different types of NAs (ETV: 1.088; TDF: 1.437; TAF: 1.318; p>0.05 for all 3 comparisons). Similarly, TDF and TAF produced no significant differences in the magnitude of HBcrAg decline at 96-week (2 .20 vs . 1 .74, p>0.05). Conclusion: The 3 first-line NAs showed similar potencies in suppression of viral activity upon 1 year duration of therapy. The lack of significant drop of HBcrAg in HBeAgnegative patients reflects the limited utility of this marker in HBeAg-negative phase. [https://doi.org/10.1002/hep.30941 ] | - |
dc.language | eng | - |
dc.publisher | John Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/ | - |
dc.relation.ispartof | Hepatology | - |
dc.relation.ispartof | The 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD): The Liver Meeting 2019 | - |
dc.title | Serum HBcrAg Profiles in Chronic Hepatitis B Patients Treated With First-Line Oral Antiviral Therapy | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Wong, DKH: danywong@hku.hk | - |
dc.identifier.email | Seto, WKW: wkseto@hku.hk | - |
dc.identifier.email | Fung, JYY: jfung@hkucc.hku.hk | - |
dc.identifier.email | Lai, CL: hrmelcl@hkucc.hku.hk | - |
dc.identifier.email | Yuen, RMF: mfyuen@hku.hk | - |
dc.identifier.authority | Wong, DKH=rp00492 | - |
dc.identifier.authority | Seto, WKW=rp01659 | - |
dc.identifier.authority | Fung, JYY=rp00518 | - |
dc.identifier.authority | Lai, CL=rp00314 | - |
dc.identifier.authority | Yuen, RMF=rp00479 | - |
dc.identifier.hkuros | 309228 | - |
dc.identifier.volume | 70 | - |
dc.identifier.issue | Suppl. 1 | - |
dc.identifier.spage | 292A | - |
dc.identifier.epage | 292A | - |
dc.identifier.isi | WOS:000488653501027 | - |
dc.publisher.place | United States | - |
dc.identifier.issnl | 0270-9139 | - |